Navigation Links
Quest PharmaTech Announces Interim Results from Phase I/II Clinical Trial for Photodynamic Treatment for Hair Removal

TSX Venture: QPT

EDMONTON, June 25 /PRNewswire-FirstCall/ - Quest PharmaTech Inc. (TSX-V: QPT), ("Quest" or the "Company"), today announced interim results from its Phase I/II clinical study designed to investigate appropriate treatment parameters for the potential use of its proprietary compound SL017 for hair removal applications. The interim results represent data from the first 80 patients enrolled in the targeted 100-patient clinical trial.

"The Phase I/II interim results demonstrated that SL017 is safe and well tolerated when used either alone or in combination with photo activation," said Madi Madiyalakan, Chief Executive Officer of Quest. "These results, along with results from the previous clinical trial, support the utility of SL017 for hair removal applications, especially for those who do not benefit from light treatment alone."

To permanently remove unwanted hair, existing laser hair removal techniques require four to eight treatments, and provide only a 75 to 85 percent permanent hair reduction in a limited patient population. The professional laser hair removal market is estimated to be $5 billion worldwide.

Quest is developing SL017 photodynamic therapy (PDT) as a potential hair removal solution that is effective across a broad patient population including those with light colored hair (for example, grey or blonde hair). In a Phase I clinical trial, Quest demonstrated the preferential localization of SL017 in hair follicles, which suggested that cutaneous PDT with SL017 has potential for permanent hair removal applications.

The Phase I/II trial of SL017 was designed to evaluate the effect of skin treatment on follicular uptake of SL017, assess the tolerable light dose on healthy subjects, and subsequently, determine the efficacy of hair removal under optimal treatment conditions. Results from this study will be used to guide the design of future clinical development.

Skin Pretreatment and Follicular Uptake

Thirty healthy subjects were enrolled to evaluate the efficacy of five different skin preparation techniques to enhance the follicular localization of SL017. One of the five skin pretreatments demonstrated a statistically significant improvement in both the intensity of follicular uptake of SL017 and the depth of penetration of SL017 in the hair follicle compared to the other skin pretreatments.

Light Dose Escalation

Forty subjects with dark colored hair and 10 subjects with light colored hair were enrolled to evaluate the safety and efficacy of combining SL017 with increasing doses of Intense Pulse Light (IPL) ranging from 4.5J/cm(2) to 20.0J/cm(2). No skin pretreatment technique was used. No unexpected side effects were observed at any of the light doses tested. A hair count was taken at days 0 and 42 in each population. There was no statistically significant improvement in hair count reduction observed in the subjects treated with SL017 PDT compared to IPL treatment alone at any of the IPL doses or in either of the two hair populations studied. However, 25% of the dark colored hair population, or 10 subjects, that were non-responsive to IPL treatment demonstrated a statistically significant reduction in hair count when treated with SL017 PDT.

Hair Removal Efficacy Under Optimal Conditions

Quest is currently enrolling 20 additional patients, 10 with dark colored hair and 10 with light colored hair, to evaluate the efficacy of SL017 PDT compared to IPL at the optimal light dose and after skin pretreatment. The 20 subjects with light colored hair enrolled in the trial will also undergo two SL017 PDT treatments. The hair growth of these patients will be monitored for up to six months. Results from this part of the study are anticipated by end of 2008.

"Based on the results we receive from these clinical studies in hair removal and the preclinical work we are currently conducting for the treatment of acne, we intend to advance SL017 PDT for one or more clinical indications," stated Thomas Woo, M.Sc., Vice President for Drug Development of Quest.

The Principal Investigator for Quest's Phase I/II hair removal trial is Dr. Robert Bissonnette, M.D., President of Innovaderm Research in Montreal.

About SL017: SL017 is a proprietary, non-toxic drug that, once applied to a target area and activated by light, is transformed into a potent cytotoxic agent that selectively destroys targeted tissue. Using this process, known as photodynamic therapy (PDT), SL017 can be applied to treat a variety of skin conditions, including hair removal, actinic keratosis and acne. The safety and potential utility of SL017 for the treatment of actinic keratosis has been demonstrated in a Phase I Clinical Study.

About Quest PharmaTech Inc.: Quest is a publicly traded, Alberta-based pharmaceutical company committed to the development and commercialization of new pharmaceutical products. It is developing a series of products for the treatment of cancer and dermatological conditions based on its unique photodynamic and sonodynamic therapy platform.

"TSX Venture Exchange has neither approved nor disapproved of the

information herein."

SOURCE Quest PharmaTech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ImmuneRegen Responds to Defense Threat Reduction Agency Request for Information
2. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
3. Quest Diagnostics to Speak at the 2007 UBS Global Life Sciences Conference
4. VioQuest Pharmaceuticals to Present at BIO InvestorForum in San Francisco
5. Quest Diagnostics Joins National ePrescribing Patient Safety Initiative (NEPSI)
6. University HealthSystem Consortium Chooses SciQuest to Optimize Medical Research Procurement
7. VioQuest Pharmaceuticals to Present at the Paramount BioSciences Healthcare Conference
8. Sinovac Requests Extension for Annual Shareholders Meeting
9. Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants
10. AmSurg Selects SciQuest Eprocurement Solution to Automate Purchasing of Medical Goods and Services
11. Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight Technology
Post Your Comments:
(Date:11/30/2015)... BOCA RATON, Florida and MAGDEBURG, Germany ... European Congress of NeuroRehabilitation (ECNR) in Vienna, ... --> 3rd European Congress of NeuroRehabilitation (ECNR) in ... 1-4, 2015. --> NovaVision, a wholly owned subsidiary ... launching the European version of its Internet-delivered NovaVision Therapy Suite ...
(Date:11/27/2015)... Kingdom , Nov. 27, 2015 /PRNewswire/--  Mallinckrodt plc ... company, announced today that it has closed the sale ... business to Guerbet (GBT- NYSE Euronext) in a transaction ... encompassed four manufacturing facilities and a total of approximately ... in the St. Louis area. ...
(Date:11/25/2015)... 2015 --> ... - 2020 report analyzes that automating biobanking workflow ... in long-term samples, minimizing manual errors, improving the ... manual errors such as mislabeling or inaccurate sample ... plays a vital role in blood fractionation, DNA ...
(Date:11/25/2015)...  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced ... of Neurocrine Biosciences, will be presenting at the 27th ... York . .   ... minutes prior to the presentation to download or install ... be available on the website approximately one hour after ...
Breaking Biology Technology:
(Date:11/2/2015)... 2, 2015  SRI International has been awarded a ... development services to the National Cancer Institute (NCI) PREVENT ... scientific expertise, modern testing and support facilities, and analytical ... and toxicology studies to evaluate potential cancer prevention drugs. ... PREVENT Cancer Drug Development Program is an NCI-supported pipeline ...
(Date:10/29/2015)... Mich. , Oct. 29, 2015  Rubicon ... Genomics for U.S. distribution of its DNA library ... kit and Rubicon,s new ThruPLEX Plasma-seq kit. ThruPLEX ... enable the preparation of NGS libraries for liquid ... for diagnostic and prognostic applications in cancer and ...
(Date:10/27/2015)... , Oct. 27, 2015 In the present ... of concern for various industry verticals such as banking, ... to the growing demand for secure & simplified access ... ,sectors, such as hacking of bank accounts, misuse of ... equipment such as PC,s, laptops, and smartphones are expected ...
Breaking Biology News(10 mins):